AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7847611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g ethanol/kg body weight
Number of subjects: 9
Study 7847611 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 9
Study 3166107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (300 mg) taken orally once a week
Number of subjects: 101
Study 3166107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 29554400 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior palatoplasty
Number of subjects: 45
Study 29554400 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatal flap procedure
Number of subjects: 45
Study 29354955 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing‐reducing manipulation with 'guoyanre' manipulation
Number of subjects: 68
Study 29354955 — intervention group
Group type: COMPARATOR
Intervention: Reinforcing‐reducing method
Number of subjects: 68
Study 25775675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stent placement
Number of subjects: 246
Study 25775675 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 246
Study 25775675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study 23993259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times daily
Number of subjects: 1497
Study 23993259 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1497
Study 23993259 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrex 200 mg daily
Number of subjects: 1497
Study 23993259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study 20584708 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 110
Study 20584708 — intervention group
Group type: COMPARATOR
Intervention: Ringer
Number of subjects: 110
Study 20584708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 18271901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lithium levels of 0.6-0.75 mmol/L
Number of subjects: 0
Study 18271901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lithium levels >0.75 mmol/L
Number of subjects: 0
Study 18271901 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt reduction of serum lithium levels >0.2 mmol/L
Number of subjects: 0
Study 18271901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lithium level of 0.4 mmol/L
Number of subjects: 0
Study 16049976 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Examination of the Breast (CBE) carried out by trained nurses, with 5 annual screenings planned.
Number of subjects: 151168
Study 16049976 — intervention group
Group type: EXPERIMENTAL
Intervention: CBE intervention
Number of subjects: 151168
Study 14624369 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) plus nevirapine
Number of subjects: 0
Study 14624369 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 nucleoside reverse‐transcriptase inhibitors (NRTIs) plus nevirapine
Number of subjects: 0
Study 10355238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lists of words that were associates of a common word (critical target)
Number of subjects: 0
Study 10355238 — intervention group
Group type: EXPERIMENTAL
Intervention: List generated from 'king'
Number of subjects: 0
Study 9097716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral and cholesterol depositions in the tissues of patients
Number of subjects: 10
Study 9097716 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy with energy dispersive x‐ray analyses (microprobe‐SEM/EDXA) and atomic absorption spectroscopy (AAS)
Number of subjects: 10
Study 9097716 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized cations imbalance
Number of subjects: 10
Study 2085103 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk protein (HMP)
Number of subjects: 20
Study 2085103 — intervention group
Group type: COMPARATOR
Intervention: Adapted cow's milk protein (CMP)
Number of subjects: 20
Study 2085103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HMP and CMP
Number of subjects: 20
Study 391628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 100
Study 391628 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 100
Study 31126775 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar Resurfacing (PR)
Number of subjects: 84
Study 31126775 — intervention group
Group type: COMPARATOR
Intervention: Non-Patellar Resurfacing (non-PR)
Number of subjects: 84
Study 27512098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tui Na therapy
Number of subjects: 90
Study 27512098 — intervention group
Group type: COMPARATOR
Intervention: Placebo Tui Na therapy
Number of subjects: 90
Study 25561389 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (multimedia information including a movie on third molar extraction)
Number of subjects: 333
Study 25561389 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (basic information given verbally)
Number of subjects: 333
Study 25561389 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic information given verbally without operative procedures and recovery information)
Number of subjects: 333
Study 24955104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaoshi Jifa treatment
Number of subjects: 27
Study 24955104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 21840846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low spatial frequency (SF) gratings (magnocellularly biased)
Number of subjects: 0
Study 21840846 — intervention group
Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF) gratings (parvocellularly biased)
Number of subjects: 0
Study 21840846 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 0
Study 19465233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg per day
Number of subjects: 9795
Study 19465233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study 17251982 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg b.i.d. for 6.5 days with rifampin 600 mg once a day
Number of subjects: 0
Study 17251982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study 17251982 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 125 mg b.i.d. for 6.5 days
Number of subjects: 0
Study 16050851 — intervention group
Group type: EXPERIMENTAL
Intervention: CKTnI testing
Number of subjects: 392
Study 16050851 — intervention group
Group type: COMPARATOR
Intervention: CK testing alone
Number of subjects: 392
Study 11967516 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg capsule per day for 6 months)
Number of subjects: 66
Study 11967516 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 66
Study 9480948 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/Pro/fat (66% CHO, 23% Pro, 11% fat)
Number of subjects: 10
Study 9480948 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (1 g/kg)
Number of subjects: 10
Study 9480948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 10
Study 7659630 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care project aimed at improving information and communication
Number of subjects: 177
Study 7659630 — intervention group
Group type: COMPARATOR
Intervention: Pre-project evaluation
Number of subjects: 177
Study 3233720 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical tooth stimulation at varying intensities
Number of subjects: 8
Study 30305049 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 prepaid incentive check
Number of subjects: 0
Study 30305049 — intervention group
Group type: COMPARATOR
Intervention: $50 promised (postpaid) incentive check
Number of subjects: 0
Study 28664840 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% or 15% citrate anticoagulation
Number of subjects: 140
Study 25532460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 192
Study 25532460 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 192
Study 23549037 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with cisplatin
Number of subjects: 433
Study 23549037 — intervention group
Group type: COMPARATOR
Intervention: Treatment without cisplatin
Number of subjects: 433
Study 23549037 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1 positive patients
Number of subjects: 433
Study 23549037 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 Gln/Gln genotype
Number of subjects: 433
Study 20511564 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-phosphate cement (Ca-PO(4)) used for indirect pulp-capping with acid conditioning prior to application.
Number of subjects: 0
Study 20511564 — intervention group
Group type: COMPARATOR
Intervention: Calcium-phosphate cement (Ca-PO(4)) used for indirect pulp-capping without acid conditioning.
Number of subjects: 0
Study 20511564 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (control).
Number of subjects: 0
Study 18179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (8 visits, 1 hour each, over 18 months) by experienced home nurses with telephone follow-up.
Number of subjects: 330
Study 18179482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 330
Study 20233343 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 36
Study 20233343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16298751 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fruit (blueberries) consumption (250 g) for three weeks
Number of subjects: 20
Study 16298751 — intervention group
Group type: COMPARATOR
Intervention: Acute fruit ingestion (250 g)
Number of subjects: 20
Study 11573659 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and alfentanil
Number of subjects: 40
Study 11573659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those who did not respond to commands)
Number of subjects: 40
Study 9692416 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 82
Study 9692416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 82
Study 9692416 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 82
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular ectopy of more than 100 beats during the day
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular ectopy of more than 100 beats at night
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal ventricular ectopic beats during the day
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal ventricular ectopic beats at night
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinoatrial pauses exceeding 1.5 seconds during the day
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinoatrial pauses exceeding 1.5 seconds
Number of subjects: 480
Study 7888847 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time multifocal ventricular ectopy
Number of subjects: 480
Study 7888847 — intervention group
Group type: COMPARATOR
Intervention: Findings on ambulatory electrocardiography
Number of subjects: 480
Study 3109146 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g Mezlocillin administered at the time of narcosis for 20 min followed by 0.5 g Metronidazol for 10 min, given in 8-hour intervals for three days post-surgery.
Number of subjects: 50
Study 3109146 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Mezlocillin and Metronidazol) administered 30 min preoperatively and continued for three days postoperatively.
Number of subjects: 50
Study 3109146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotic treatment).
Number of subjects: 50
Study 30545653 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incisional negative pressure wound therapy (ciNPWT)
Number of subjects: 160
Study 30545653 — intervention group
Group type: COMPARATOR
Intervention: Silver-impregnated occlusive dressing (control)
Number of subjects: 160
Study 30221851 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to personalized video recordings of patient-physician counseling
Number of subjects: 101
Study 30221851 — intervention group
Group type: COMPARATOR
Intervention: No access to personalized video recordings
Number of subjects: 101
Study 26507336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Inofolic® plus): myo-inositol 4000 mg, folic acid 400 mcg, melatonin 3 mg
Number of subjects: 526
Study 26507336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Inofolic®): myo-inositol 4000 mg, folic acid 400 mcg
Number of subjects: 526
Study 26507336 — intervention group
Group type: COMPARATOR
Intervention: Control group: only folic acid 400 mcg
Number of subjects: 526
Study 25102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Core curriculum in urology clerkships
Number of subjects: 41
Study 25102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based resources during clerkship
Number of subjects: 41
Study 25102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Urology interest group
Number of subjects: 41
Study 25102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory urology clinical clerkship
Number of subjects: 41
Study 25102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective urology clerkship
Number of subjects: 41
Study 25102786 — intervention group
Group type: COMPARATOR
Intervention: No urology lectures or coursework
Number of subjects: 41
Study 24278989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 0
Study 24278989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 0
Study 24278989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19328351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy
Number of subjects: 44
Study 19328351 — intervention group
Group type: EXPERIMENTAL
Intervention: External dacryocystorhinostomy
Number of subjects: 44
Study 19328351 — intervention group
Group type: COMPARATOR
Intervention: Non-operated sides (control)
Number of subjects: 44
Study 17724259 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 17724259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 14716729 — intervention group
Group type: COMPARATOR
Intervention: Active prevention agents or placebo
Number of subjects: 0
Study 14716729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidants
Number of subjects: 0
Study 11881102 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 27
Study 11881102 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 9683207 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (stavudine and nelfinavir)
Number of subjects: 62
Study 9683207 — intervention group
Group type: COMPARATOR
Intervention: Prolonged induction therapy (saquinavir and nelfinavir)
Number of subjects: 62
Study 9683207 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (stavudine, lamivudine, saquinavir, and nelfinavir)
Number of subjects: 62
Study 7830804 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg i.m. once a week for 12 weeks, followed by tapering oral dose
Number of subjects: 15
Study 3146726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin (16 mg/kg per day)
Number of subjects: 80
Study 3146726 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporin (9 mg/kg per day) with azathioprine (1 mg/kg per day)
Number of subjects: 80
Study 3146726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin followed by conversion to azathioprine
Number of subjects: 80
Study 29265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking apple juice (0 ml, 50 ml, 100 ml, 200 ml, 300 ml, 400 ml)
Number of subjects: 60
Study 29265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value of 9.6 cm2
Number of subjects: 60
Study 29265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear predictive model based on antral cross-sectional area
Number of subjects: 60
Study 26840338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals (24±3 hours)
Number of subjects: 198
Study 26840338 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing intervals (24 hours)
Number of subjects: 198
Study 26840338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals
Number of subjects: 198
Study 26840338 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing intervals
Number of subjects: 198
Study 26840338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible and Fixed dosing intervals
Number of subjects: 198
Study 25070545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed-dose)
Number of subjects: 488
Study 25070545 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 488
Study 25070545 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 488
Study 25070545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 488
Study 23658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily)
Number of subjects: 108
Study 23658438 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (400 mg daily)
Number of subjects: 108
Study 23658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Atorvastatin + Etidronate)
Number of subjects: 108
Study 20669576 — intervention group
Group type: EXPERIMENTAL
Intervention: AO locked compressive plates (LCP)
Number of subjects: 58
Study 20669576 — intervention group
Group type: COMPARATOR
Intervention: Humeral head replacement
Number of subjects: 58
Study 18387406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral formulation
Number of subjects: 1020
Study 18387406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 16608514 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (25 g soy protein containing 60 mg isoflavones)
Number of subjects: 87
Study 16608514 — intervention group
Group type: COMPARATOR
Intervention: Control protein devoid of isoflavones
Number of subjects: 87
Study 12420194 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 23
Study 12420194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10599151 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone replacement therapy
Number of subjects: 6
Study 7499737 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms sulprostone in 250 saline solution infused at a rate of 100 micrograms/h 12 hours before the abortion
Number of subjects: 90
Study 7499737 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol per os 3 hours before abortion
Number of subjects: 90
Study 7499737 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms misoprostol per os 12 hours before abortion
Number of subjects: 90
Study 7499737 — intervention group
Group type: EXPERIMENTAL
Intervention: sulprostone
Number of subjects: 90
Study 7499737 — intervention group
Group type: COMPARATOR
Intervention: misoprostol
Number of subjects: 90
Study 1723196 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 17
Study 6258106 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-acetylenic GABA (GAG)
Number of subjects: 14
Study 30922760 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-pain walking
Number of subjects: 36
Study 30922760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-free walking
Number of subjects: 36
Study 28703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomaterial 1 (B1)
Number of subjects: 48
Study 28703478 — intervention group
Group type: EXPERIMENTAL
Intervention: BoneCeramic (BC)
Number of subjects: 48
Study 28703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomaterial 2 (B2)
Number of subjects: 48
Study 28703478 — intervention group
Group type: COMPARATOR
Intervention: Clot (C)
Number of subjects: 48
Study 25813773 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 35
Study 25813773 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 35
Study 24200700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 5 mg with sufentanil 2.5 μg followed by epidural 2% lidocaine 5 mL (Group L)
Number of subjects: 40
Study 24200700 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 10 mg with sufentanil 2.5 μg followed by epidural saline 5 mL (Group C)
Number of subjects: 40
Study 24200700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L
Number of subjects: 40
Study 24200700 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 40
Study 20939022 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening measure comprised of 13 items rated on a 4-point scale, reviewed by two program faculty members.
Number of subjects: 0
Study 19016830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 268
Study 19016830 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 268
Study 17556865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 59
Study 17556865 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 59
Study 15446522 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-PCL
Number of subjects: 344
Study 15446522 — intervention group
Group type: EXPERIMENTAL
Intervention: MLP
Number of subjects: 344
Study 15446522 — intervention group
Group type: COMPARATOR
Intervention: PS
Number of subjects: 344
Study 15446522 — intervention group
Group type: COMPARATOR
Intervention: PCL
Number of subjects: 344